NASDAQ:ATOS

Atossa Therapeutics Stock Forecast, Price & News

$1.25

0.00 (0.00 %)

(As of 01/15/2021 08:00 PM ET)

Add

Compare

Today's Range

$1.14

Now: $1.25▼

$1.36

50-Day Range

$0.85

MA: $1.09▼

$1.76

52-Week Range

$0.76

Now: $1.25▼

$5.08

Volume624,929 shs

Average Volume19.57 million shs

Market Capitalization$13.12 million

P/E RatioN/A

Dividend YieldN/A

Beta2.34

Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.

MarketRank^™

Overall MarketRank^™

1.31 out of 5 stars

3.5 Analyst's Opinion

Consensus Rating
Atossa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.50, Atossa Therapeutics has a forecasted upside of 500.0% from its current price of $1.25.
Amount of Analyst Coverage
Atossa Therapeutics has received no research coverage in the past 90 days.

2.4 Community Rank

Outperform Votes
Atossa Therapeutics has received 205 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Atossa Therapeutics has received 217 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Atossa Therapeutics has received 51.42% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Atossa Therapeutics and other stocks. Vote “Outperform” if you believe ATOS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATOS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Atossa Therapeutics does not currently pay a dividend.
Dividend Growth
Atossa Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Atossa Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 33.21% of the stock of Atossa Therapeutics is held by insiders.
Percentage Held by Institutions
Only 6.87% of the stock of Atossa Therapeutics is held by institutions.

0.6 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Atossa Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Atossa Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Atossa Therapeutics has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ATOS

Previous Symbol

CUSIPN/A

CIK1488039

Webwww.atossagenetics.com

Phone206-325-6086

Employees4

Debt

Debt-to-Equity RatioN/A

Current Ratio7.23

Quick Ratio7.23

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.37 per share

Price / Book0.91

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-17,240,000.00

Net MarginsN/A

Return on Equity-130.58%

Return on Assets-108.14%

Miscellaneous

Outstanding Shares10,493,000

Market Cap$13.12 million

Next Earnings Date3/25/2021 (Estimated)

OptionableNot Optionable

$1.25

0.00 (0.00 %)

(As of 01/15/2021 08:00 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ATOS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.

Atossa Therapeutics (NASDAQ:ATOS) Frequently Asked Questions

How has Atossa Therapeutics' stock been impacted by Coronavirus?

Atossa Therapeutics' stock was trading at $0.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ATOS stock has increased by 42.0% and is now trading at $1.25.
View which stocks have been most impacted by COVID-19.

Is Atossa Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Atossa Therapeutics stock.
View analyst ratings for Atossa Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Atossa Therapeutics?

Wall Street analysts have given Atossa Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Atossa Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Atossa Therapeutics' next earnings date?

Atossa Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for Atossa Therapeutics.

How were Atossa Therapeutics' earnings last quarter?

Atossa Therapeutics, Inc. (NASDAQ:ATOS) announced its earnings results on Wednesday, November, 18th. The company reported ($0.34) EPS for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.01.
View Atossa Therapeutics' earnings history.

When did Atossa Therapeutics' stock split? How did Atossa Therapeutics' stock split work?

Atossa Therapeutics's stock reverse split on the morning of Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Therapeutics stock prior to the reverse split would have 8 shares after the split.

What price target have analysts set for ATOS?

2 brokers have issued twelve-month price objectives for Atossa Therapeutics' shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate Atossa Therapeutics' stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 500.0% from the stock's current price.
View analysts' price targets for Atossa Therapeutics or view Wall Street analyst' top-rated stocks.

Are investors shorting Atossa Therapeutics?

Atossa Therapeutics saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 2,800,000 shares, an increase of 529.6% from the December 15th total of 444,700 shares. Based on an average daily volume of 2,370,000 shares, the days-to-cover ratio is currently 1.2 days.
View Atossa Therapeutics' Short Interest.

Who are some of Atossa Therapeutics' key competitors?

Some companies that are related to Atossa Therapeutics include Catabasis Pharmaceuticals (CATB), Sunesis Pharmaceuticals (SNSS), Edesa Biotech (EDSA), Akari Therapeutics (AKTX), Endonovo Therapeutics (ENDV), Cumberland Pharmaceuticals (CPIX), Tenzing Acquisition (TZAC), Acer Therapeutics (ACER), Regulus Therapeutics (RGLS), Forward Pharma A/S (FWP), Annovis Bio (ANVS), GT Biopharma (GTBP), Pulmatrix (PULM), Newron Pharmaceuticals (NWPHF) and Addex Therapeutics (ADDXF).
View all of ATOS's competitors.

What other stocks do shareholders of Atossa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia (NOK).

Who are Atossa Therapeutics' key executives?

Atossa Therapeutics' management team includes the following people:

Dr. Steven C. Quay, Chairman, CEO & Pres (Age 69, Pay $919.59k)
Mr. Kyle Guse CPA, Esq., CPA, CFO, Gen. Counsel & Sec. (Age 56, Pay $629.18k)
Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical Affairs

What is Atossa Therapeutics' stock symbol?

Atossa Therapeutics trades on the NASDAQ under the ticker symbol "ATOS."

How do I buy shares of Atossa Therapeutics?

Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Atossa Therapeutics' stock price today?

One share of ATOS stock can currently be purchased for approximately $1.25.

How big of a company is Atossa Therapeutics?

Atossa Therapeutics has a market capitalization of $13.12 million. Atossa Therapeutics employs 4 workers across the globe.

What is Atossa Therapeutics' official website?

The official website for Atossa Therapeutics is www.atossagenetics.com.

How can I contact Atossa Therapeutics?

Atossa Therapeutics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6086 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here